The WHO recommends preexposure prophylaxis (PrEP) in populations at substantial risk of HIV. Despite a number of randomized controlled trials demonstrating its efficacy, and several ongoing implementation projects, PrEP is currently only available in a few countries. Modelling studies can provide useful insights into the long-term impact of introducing PrEP in different subgroups of the population. The review summarizes studies that either evaluated the cost-effectiveness or the cost of introducing PrEP, focusing on seven published in the last year.
INTRODUCTION
Several guidelines and position statements have been issued recommending PrEP in people at high risk of contracting HIV to prevent HIV acquisition (see Table 1 ). The use of daily oral Truvada in HIVnegative people has been approved in the USA in 2012 [9] , whereas, in most countries, including Europe and Australia, PrEP is not available so far. Importantly, the WHO and the position released by the relevant medical associations in the UK highlighted the importance of estimating the cost-effectiveness of PrEP. The WHO, in particular, reviewed the published literature on the cost-effectiveness of PrEP and took this into account when determining the strength of the evidence in the guidelines for key populations. The WHO announced in July 2015 that updated guidance on PrEP will be released soon [10] .
The strong evidence for the effectiveness of PrEP leaves countries and health providers facing the decision of whether to fund PrEP on top of the other HIV prevention programmes already in place and, if so, to decide which subgroups should receive it. Mathematical models provide a framework to combine all the information available on PrEP (uptake, efficacy, effectiveness, adherence, sexual behaviour while on PrEP, monitoring on PrEP, and cost) to provide insights into the potential epidemiological impact, budget impact, and cost-effectiveness of PrEP at a population level. A cost-effectiveness analysis compares the cost and outcomes of two or more different options and usually involves calculation of the cost of obtaining a gain in health [years of life, quality-adjusted lifeyears (QALY), deaths averted, infections averted, or disability-adjusted life-years (DALYs) averted]. The advantage of calculating the cost per QALY gained (or, similarly, per DALY averted) is that this 'incremental cost-effectiveness ratio' (ICER) can be compared across other interventions in any disease area. Budget impact analysis, on the other hand, consists of 'assessing the financial consequences of the introduction of a new technology in a specific setting in the short-to-medium term' [11] . These methods have only been relatively recently developed, but they are becoming more and more popular, as countries need to understand, not only whether new interventions would be cost effective, but as well whether they can afford the introduction of these new technologies.
In this study, we review studies which evaluated the cost-effectiveness and/or affordability of PrEPbased HIV preventions, focussing on studies published in the past year. In particular, we aim to determine the settings and populations in which PrEP is likely to be cost effective and affordable.
A number of literature reviews on the costeffectiveness of PrEP have been performed: some specific to the USA [12] and some more general [13] . A previous literature review of cost-effectiveness studies in the USA (all in MSM) concluded that there was substantial variation in the cost per QALY gained. The wide variation reflects the variation in the effectiveness assumed as well as the different type of models used, static rather than dynamic. Gomez et al. [13] systematically reviewed the literature on cost-effectiveness of PrEP. The populations modelled were heterosexual couples, MSM and people who inject drugs in generalized and concentrated epidemics from southern Africa, Ukraine, USA, and Peru. They pointed out that offering PrEP to key populations appeared to be the most cost-effective strategy and that PrEP had the potential to be a cost-effective component of HIV prevention. The factors found to be most influential were costs, epidemic context, coverage of the prevention programme, the degree to which PrEP is targeted at population with high HIV incidence, and adherence (affecting effectiveness). We now focus on the most recent studies to add to this literature.
RECENT STUDIES: SEARCH CRITERIA AND SUMMARY OF MODELLING CONSIDERATIONS
To identify the most recent studies of interest the following terms ('cost' AND ('tenofovir' OR 'preexposure prophylaxis' OR 'chemoprophylaxis' OR 'PrEP') AND 'HIV') were used to search all databases in the Web of Science, starting from 1st July 2014. Eighty-three abstracts were retrieved and seven were identified as eligible as they contained either an evaluation of the cost-effectiveness of PrEP or an estimation of the cost of delivering PrEP (see Table 2 ).
In terms of the type of mathematical model used in these seven studies, one used a static decision model [14 && ], three a dynamic deterministic compartmental model [15 & ,18 && ,19 && ], one a dynamic stochastic microsimulation model [17 && ], whereas two did not use mathematical models, either because they simply used the number needed to treat to estimate the average cost of the PrEP interventions to prevent one infection [16 && ] or estimated the resources required to deliver PrEP and did not evaluate the cost-effectiveness of introducing it [24] . The difference between static and dynamic models is that static models, typically used in health economics, do not take into account the fact that HIV is an infectious diseases and therefore that by preventing directly one infection, more (secondary) infections are likely to be averted [25] .
KEY POINTS
Based on studies in the past year, among MSM in North America the estimated cost-effectiveness of PrEP ranges from cost saving to $160 000/QALY gained reflecting differences in efficacy (86 vs 44%) and type of model used.
Among heterosexual sero-different couples the introduction of PrEP is cost effective in South Africa when considering a relatively short-term use (until 1 year after the HIV-positive partner has initiated ART), but not in Uganda, unless we consider the cost per infection averted. In Nigeria, the introduction of PrEP was not found to be cost effective on its own, but was in combination with condom promotion and offer of ART at diagnosis, after these have been implemented.
To help decisions of public funding of PrEP, given the current economic situation, efforts should be made to evaluate not only the cost-effectiveness but also the budget impact of PrEP.
All recent cost-effectiveness studies published as manuscripts find circumstances (e.g. higher prevalence, as a proxy of HIV incidence, short-term use during a period of high risk, higher adherence and therefore effectiveness, in combination with ART at diagnosis and condom promotion, or with high-clinical capacity) in which PrEP, in principle, could be cost effective if not cost saving.
It is now time to consider in more detail the PrEP implementation factors, including the uptake, the actual way of identifying subgroups of the population at high risk of contracting HIV, the length of the PrEP intervention, related to the actual risk, and clearly the actual cost of delivering PrEP. Table 1 . Cost is mentioned as a concern if PrEP had to be widespread used in the UK. In addition, they stated that 'It is imperative to gather evidence for the value of PrEP in the UK'
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Europe ECDC Evidence suggests that the use of preexposure prophylaxis (PrEP) for men who have sex with men (MSM) is an effective HIV prevention tool for Europe Only one study considered the potential impact of a decrease in condom use in people receiving PrEP [14 && ] and none of them considered other possible negative consequences of PrEP: such as the development of resistance or toxicities because of PrEP, however, there is no evidence from the randomized controlled trials for these to be major issues.
RECENT STUDIES: COST-EFFECTIVENESS PARAMETERS
The cost assumed for 1 year of PrEP varies substantially across studies, mainly driven by the setting. In South Africa and Nigeria this was assumed to be around $250 per year [ && ] reported this explicitly. They used a cost-effectiveness threshold of three times gross domestic product (GDP) per capita to be cost effective and one time GDP per capita to be considered very cost-effective [28] , as was used in previous WHO material, which is considered unlikely for low and middle-income countries, given in the UK it has been estimated to be around 0.4 of the GDP per capita [29] .
COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS IN MSM IN NORTH AMERICA
Chen and Dowdy [14 && ] estimated the introduction of PrEP for 1 year (44% efficacious) among HIVnegative MSM living in the USA will cost $160 000/QALY gained over a lifetime horizon (95% uncertainty range: cost-saving to $740 000) in the base case. However, they considered alternative scenarios which made PrEP cost-saving (when an HIV prevalence of 0.35 and high adherence to PrEP -such that the PrEP efficacy was 92%were assumed) and on the other hand scenarios which increased the ICER up as far as $840/QALY gained (in the case of 100% condom use).
Most recently, Ouellet et al. [16 && ] evaluated the cost-effectiveness of 1 year of 'on demand' PrEP (as used in the IPERGAY trial [30] ), among noninjection drug-using MSM in Canada. They used the number -needed-to-treat (51.78), estimated from the iPrEx trial, to calculate the total number of noninjection drug-using MSM needed to be on PrEP to prevent one HIV infection and estimated the lifetime cost of living with HIV, assuming infections occur at age 30, with a life-expectancy of 35.2 years. They found that at 0 and 3% discount rates the PrEP intervention was cost-saving, whereas when using a 5% discount rate the ICER varied from Canadian $47 338/QALY gained, in the most expensive scenario (1 Canadian $ ¼ 0.98 US$), to Canadian $60 223 in the least expensive case.
The three studies [14 && ,15 & ,16 && ] present significant differences in the base case ICER: from cost-saving [16 && ] to $160 000/QALY gained [14 && ]. However, given Chen and Dowdy used a static model, which does not take into account secondary infections averted, we would expect this study to obtain less favourable ICERs. In addition, even this study found PrEP to be a cost-saving option in situations characterized by high adherence (corresponding to a PrEP efficacy of 92%) and being used in a high HIV prevalence population (0.35). Importantly, studies recently published on the costeffectiveness of PrEP in high-income countries have started taking a societal perspective, allowing them to take into account the cost incurred by the entire society and therefore some of the advantages of keeping people free from HIV. Unfortunately, none of these studies conducted a budget impact analysis necessary to determine its affordability.
COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS AMONG SERO-DIFFERENT COUPLES IN AFRICA
Before this last year, only one study had evaluated the cost-effectiveness of PrEP among sero-different couples [31] . They had found that PrEP could be highly cost effective in this population group and even cost-saving. They estimated that if the annual cost of PrEP is less than 40% the annual cost of ART and if PrEP is more than 70% effective then offering PrEP to the HIV-negative partner could be at least as cost effective as initiating ART earlier in the positive one.
Recently, three studies evaluated the costeffectiveness of PrEP among sero-different couples in Africa [17
. Jewell et al. [17 && ] envisaged an intervention where PrEP (90% efficacious against HIV) would be used by the HIV uninfected partner of serodifferent couples living in South Africa before the HIV-positive partner initiates ART and for one year thereafter. They found that this intervention with (33% efficacy against herpes simplex virus-2 (HSV-2)) or without protection against HSV-2, would be cost effective, with ICERs (over 20 year time horizon) of respectively $9757 and $10 383/ DALY averted (South Africa GDP in 2012 $7314). In the sensitivity analyses they found that if all couples were sero-different not only for HIV but for HSV-2 as well, the ICER could be further reduced to $1445/DALY averted.
Mitchell et al. [18 && ] compared the costeffectiveness of condom promotion, treatment as prevention (TasP), PrEP, and their combination against a baseline scenario characterized by eligibility criteria for ART initiation of CD4 þ 350 cells/ ml for sero-different couples in Nigeria. They found that the most cost-effective strategy was condom promotion with an ICER of $1206/DALY averted, followed by condom promotion in combination with TasP (ICER: $1607/DALY averted), followed by the addition of PrEP (ICER: $7870/DALY averted). The order of incrementally cost-effective interventions remained the same when varying the discount rate (range: 3-15%), initial PrEP coverage (range: 40-80%), or initial condom promotion coverage (range: 40-80%). However, with a discount rate of 3% (more commonly used, rather than 10%) and with lower initial condom promotion coverage, the ICERs are reduced. When considering a time frame of 10 years (rather than 20), the most cost-effective intervention became TasP, followed by condom promotion along with TasP, whereas when considering a lifetime frame, the ICERs are improved. This is because of the fact that TasP will have a more immediate effect in averting DALYs by improving survival in people at low CD4 þ , whereas the introduction of PrEP has an effect on DALYs later in time, by averting HIV infections. Ying et al. [19 && ] estimated the cost-effectiveness of a short-term use of PrEP in HIV-negative partners of high-risk serodifferent couples in Uganda. The PrEP intervention is similar to the one described by Jewell et al. [17 && ], but until 6 rather than 12 months after the HIVpositive partner's ART initiation and in combination with an increase in ART coverage (assumed currently 40% in Uganda) among the HIV-positive partners of high-risk sero-different couples. They reported that this intervention would be very cost effective in terms of HIV infections averted, but not cost effective in terms of cost per DALY averted ($5334/DALY). They found that clinical capacity played an important role with ICER varying from $4648/DALY averted with high-clinical capacity (1500 couples annually) to $18 151/DALY averted with low-clinical capacity (200 couples annually). When varying other relevant assumptions (ART cost at $100/person-year, rather than $269/person-year, discount rate of 0%, rather than 3% and drop-out from ART and PrEP programme of 10%, rather than 3%) the PrEP intervention remains cost effective for averting DALYs but not very cost-effective, whereas it remains the most cost-effective strategy for averting HIV infections across all ranges of assumptions.
These three studies considered a relatively similar PrEP intervention in sero-different couples, all using dynamic models and with a relatively short time frame, either 10 or 20 years. The cost-effectiveness of the PrEP intervention alone, assessed by Mitchell et al. and Jewell et al., varied from being dominated (meaning that the intervention costs more and is no more effective than the comparator) in Nigeria to a cost of around $10 000/DALY averted in South Africa, where it is cost-effective. When considering the combination of the PrEP intervention with condom promotion and TasP in Nigeria, the addition of PrEP was cost effective only after condom promotion and condom promotion in combination with TasP at an ICER of $7870/DALY averted, whereas in Uganda a programme of PrEP and ART in high-risk couples cost $5334/DALY averted, which means PrEP is unlikely to be cost effective in these circumstances. The ICER threshold for an intervention to be considered cost effective is the subject of much debate, and the often used threshold of one or three time the per capita GDP is widely considered to be too high [32] .
The difficulty in comparing these estimates comes from the fact the possible scenarios included differs and so do the countries where these studies are set. In particular there are substantial differences in terms of HIV incidence assumed in these couples (2.7 per 100 person-years in the study set in South Africa [17 && ] to 5 per 100 person-years in the study set in Nigeria [18 && ]), ART eligibility and coverage in the reference scenario (CD4 þ < 350 cells/ml in the studies set in South Africa and Nigeria, with assumed ART coverage of 100% in Nigeria and of CD4 þ < 500 cells/ml with 40% ART coverage in the study in Uganda) and the cost-effectiveness threshold, which is based on the GDP per capita ($11 440 for South Africa, $2742 for Nigeria, and $1681 for Uganda). When considering the parameters varied in sensitivity analyses in these three studies, they do not overlap. The parameters that were significantly affecting the results are the proportion of couples sero-different for both HIV and HSV-2 in Jewell et al. [ 
CONCLUSION
There has been a move for studies of cost-effectiveness of PrEP to focus on populations at high risk of contracting HIV. All the studies published in the last year all focused on some of the key populations: MSM in high income countries and sero-different couples in African countries. In addition, those among sero-different couples envisaged a shortterm PrEP intervention but in a period of time in which the HIV-negative person is considered at high risk of contracting HIV. Clearly offering PrEP to subgroups of the population and for periods of time where the person is at particularly high risk helps to improve the cost-effectiveness of PrEP. However, identification and successful targeting of these subgroups at higher risk of contracting HIV is not always straightforward.
In addition, some studies [13] concluded that the maximum benefit from PrEP introduction could be realized if introduced in combination with HIV prevention programmes.
Compared with the previous cost-effectiveness studies of PrEP reviewed, some of the recent studies developed further investigation of the role of other prevention interventions (such as expansion of HIV testing and ART) in combination or as alternatives to PrEP, some [18 && ] found that PrEP would not be the most cost effective, but all found it to be cost effective as an addition (when considering a time frame of 20 years). Unfortunately, most studies do not report the HIV incidence which is clearly a key parameter in determining the cost-effectiveness of PrEP introduction (with PrEP more likely to be cost-effective if incidence is high) and that could help explain the difference in results. The appropriate cost-effectiveness threshold to be used in a given setting remains a key issue that is not fully resolved.
The other crucial element to determine the costeffectiveness of any intervention is clearly its cost and the cost of its delivery. Ongoing implementation projects are paramount to inform countries on how to deliver PrEP (who, where, how), how much it will cost and what level of capacity is necessary to make it cost effective. Most of the studies presented cost-effectiveness analyses, but not budget impact analyses, with the exception of Ying et al. which estimated, by conducting a microcosting study, the expenditure within a PrEP implementation project, and extrapolated the cost if the programme was to be run by the government. Budget impact analyses are extremely important for health providers when implementing a new technology and are increasingly requested by reimbursement authorities [33] . The cost-effectiveness of an intervention does not in itself imply affordability. This means that even if an intervention is found cost effective and if the country typically uses this criterion to decide on how to distribute the resources on health, this does not mean it will make the policy decision to pay to introduce them. The use of sofosbuvir for treatment of hepatitis C is an example of this in the UK [34] ).
